ERBB3 EXPRESSION

CI-VAR-00000913Explore in graph →CIViC 361

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
ERBB3 EXPRESSION	Anti-ErbB3 Monoclonal Antibody AV-203	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID862 The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict r… (full text at CIViC) PMID 25542901 · Meetze et al., 2015 · Open in CIViC	civic
Melanoma1
ERBB3 EXPRESSION	Pertuzumab	Predictive	D	Supports Sensitivity Response	3	submitted	EID3051 A preclinical study demonstrating that in a subgroup of BRAF/NRAS wildtype/wildtype showing high levels of phospho-ErbB3, knockdown of NRG1 reduced viability and decreased activation of ErbB3, ErbB2 a… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Pancreatic Ductal Adenocarcinoma1
ERBB3 EXPRESSION	9F7-F11 + PertuzumabCombination	Predictive	D	Supports Sensitivity Response	3	accepted	EID865 In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agen… (full text at CIViC) PMID 25216528 · Thomas et al., 2014 · Open in CIViC	civic